ERBB2 and breast cancer: Herceptin-induced growth inhibition was lost in breast cancer cells that overexpressed both HER2 and IGF-1R, and the growth arrest was regained when IGF binding protein-3 (IGFBP-3), which blocked IGF-induced IGF-1R signaling, was added21.